These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 27034722)

  • 1. Managing chronic bladder diseases with the administration of exogenous glycosaminoglycans: an update on the evidence.
    Lazzeri M; Hurle R; Casale P; Buffi N; Lughezzani G; Fiorini G; Peschechera R; Pasini L; Zandegiacomo S; Benetti A; Taverna G; Guazzoni G; Barbagli G
    Ther Adv Urol; 2016 Apr; 8(2):91-9. PubMed ID: 27034722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GAG replenishment therapy for bladder pain syndrome/interstitial cystitis.
    Wyndaele JJJ; Riedl C; Taneja R; Lovász S; Ueda T; Cervigni M
    Neurourol Urodyn; 2019 Feb; 38(2):535-544. PubMed ID: 30592544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GAG layer replenishment therapy for chronic forms of cystitis with intravesical glycosaminoglycans--a review.
    Madersbacher H; van Ophoven A; van Kerrebroeck PE
    Neurourol Urodyn; 2013 Jan; 32(1):9-18. PubMed ID: 22782909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravesical glycosaminoglycans in the management of chronic cystitis.
    Iacovelli V; Topazio L; Gaziev G; Bove P; Vespasiani G; Finazzi Agrò E
    Minerva Urol Nefrol; 2013 Dec; 65(4):249-62. PubMed ID: 24091478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interstitial cystitis/bladder pain syndrome and glycosaminoglycans replacement therapy.
    Cervigni M
    Transl Androl Urol; 2015 Dec; 4(6):638-42. PubMed ID: 26816865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of sodium hyaluronate and sodium chondroitin sulphate in the management of bladder disease.
    Damiano R; Cicione A
    Ther Adv Urol; 2011 Oct; 3(5):223-32. PubMed ID: 22046200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyaluronic acid and chondroitin sulfate, alone or in combination, efficiently counteract induced bladder cell damage and inflammation.
    Stellavato A; Pirozzi AVA; Diana P; Reale S; Vassallo V; Fusco A; Donnarumma G; De Rosa M; Schiraldi C
    PLoS One; 2019; 14(6):e0218475. PubMed ID: 31237905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Painful bladder syndrome and interstitial cystitis: treatment options.
    Fiander N
    Br J Nurs; 2013 May 9-22; 22(9):S26, S28-33. PubMed ID: 23752572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycosaminoglycan Replacement Therapy with Intravesical Instillations of Combined Hyaluronic Acid and Chondroitin Sulfate in Patients with Recurrent Cystitis, Post-radiation Cystitis and Bladder Pain Syndrome: A Narrative Review.
    Poletajew S; Brzózka MM; Krajewski W; Kamecki H; Nyk Ł; Kryst P
    Pain Ther; 2024 Feb; 13(1):1-22. PubMed ID: 37917298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical comparison of intravesical hyaluronic acid and chondroitin sulfate therapies in the treatment of bladder pain syndrome/interstitial cystitis.
    Gülpınar Ö; Esen B; Kayış A; Gökçe Mİ; Süer E
    Neurourol Urodyn; 2018 Jan; 37(1):257-262. PubMed ID: 28480984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ls clinical practice aligned with the latest scientific evidence on GAG therapy?
    Janssen DAW
    Urologia; 2017 Sep; 84(Suppl 1):16-20. PubMed ID: 28862729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the metabolism of glycosaminoglycans in patients with interstitial cystis.
    Lucon M; Martins JR; Leite KR; Soler R; Nader HB; Srougi M; Bruschini H
    Int Braz J Urol; 2014; 40(1):72-9. PubMed ID: 24642152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The association of elevated urinary total to sulfated glycosaminoglycan ratio and high molecular mass hyaluronic acid with interstitial cystitis.
    Wei DC; Politano VA; Selzer MG; Lokeshwar VB
    J Urol; 2000 May; 163(5):1577-83. PubMed ID: 10751891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of refractory interstitial cystitis/painful bladder syndrome with CystoProtek--an oral multi-agent natural supplement.
    Theoharides TC; Kempuraj D; Vakali S; Sant GR
    Can J Urol; 2008 Dec; 15(6):4410-4. PubMed ID: 19046494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyaluronan nanoplatelets exert an intrinsic anti-inflammatory activity in a rat model of bladder painful syndrome/interstitial cystitis.
    Diaz-Salmeron R; Cailleau C; Denis S; Ponchel G; Bouchemal K
    J Control Release; 2023 Apr; 356():434-447. PubMed ID: 36921722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravesical chondroitin sulfate inhibits recruitment of inflammatory cells in an acute acid damage "leaky bladder" model of cystitis.
    Engles CD; Hauser PJ; Abdullah SN; Culkin DJ; Hurst RE
    Urology; 2012 Feb; 79(2):483.e13-7. PubMed ID: 22137543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravesical treatments for painful bladder syndrome/ interstitial cystitis.
    Dawson TE; Jamison J
    Cochrane Database Syst Rev; 2007 Oct; (4):CD006113. PubMed ID: 17943887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Available evidence about efficacy of different restoring agents of glycosaminoglycans for intravesical use in interstitial cystitis].
    Arance I; Ramón de Fata F; Angulo JC; González-Enguita C; Errando C; Cozar JM; Esteban M
    Actas Urol Esp; 2013 Feb; 37(2):92-9. PubMed ID: 23260184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of anti-microbial peptide LL-37-induced apoptosis and ATP release in the urinary bladder by a modified glycosaminoglycan.
    Lee WY; Savage JR; Zhang J; Jia W; Oottamasathien S; Prestwich GD
    PLoS One; 2013; 8(10):e77854. PubMed ID: 24204996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GAGs and GAGs diseases: when pathophysiology supports the clinic.
    Costantini E; Lazzeri M; Porena M
    Urologia; 2013; 80(3):173-8. PubMed ID: 24526593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.